Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

• Results Overview

  Dupilumab significantly improved eczema symptoms, itching, and quality of life in adolescents with moderate-to-severe atopic dermatitis compared to placebo, with an acceptable safety profile.

• Study Summary

  Num Participants:

  251

  Study Type:

  Rct

  Control Group:

  Placebo Every 2 Weeks

  Efficacy End Points Treatment:

  {'EASI-75': 41.5, 'IGA 0/1': 24.4, 'Peak Pruritus NRS': -47.9}

  Efficacy End Points Control:

  {'EASI-75': 8.2, 'IGA 0/1': 2.4, 'Peak Pruritus NRS': -19.0}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Conjunctivitis	Low	9.8
  Injection Site Reactions	Low	8.5
  Skin Infections (Non-Herpetic)	Medium	9.8

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Conjunctivitis	Low	4.7
  Injection Site Reactions	Low	3.5
  Skin Infections (Non-Herpetic)	Medium	18.8